Related Experiment Video
Updated: May 13, 2026
09:58
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling
A Caldarelli1, J P Müller, M Paskowski-Rogacz
1Department of Medical Systems Biology, University Hospital and Medical Faculty Carl Gustav Carus, University of Technology Dresden, Dresden, Germany.
Leukemia
|March 20, 2013
Summary
Fms-like tyrosine kinase-3 internal-tandem duplication (FLT3-ITD) drives acute myeloid leukemia by activating STAT5. Targeting intracellular protein transport, specifically KDELR1, reduces FLT3-ITD signaling and leukemia progression.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Fms-like tyrosine kinase-3 (FLT3) mutations, particularly internal-tandem duplications (FLT3-ITD), are prevalent in acute myeloid leukemia (AML).
- FLT3-ITD mutations lead to aberrant signaling, including constitutive activation of STAT5, promoting leukemogenesis.
Purpose of the Study:
- To identify novel therapeutic targets by screening for genes that modulate FLT3-ITD-mediated STAT5 signaling.
- To investigate the role of intracellular protein transport pathways in FLT3-ITD-driven AML.
Main Methods:
- An esiRNA-based RNA interference (RNAi) screen using a STAT5-driven reporter assay was employed.
- Functional assays including proliferation, colony formation, and in vivo leukemia models were utilized.
- KDELR1, a key protein in Golgi-ER retrograde transport, was specifically investigated.
Main Results:
- RNAi screening identified genes involved in protein secretion and intracellular transport as regulators of FLT3-ITD signaling.
- Downregulation of KDELR1 in FLT3-ITD-positive cell lines (MV4-11, 32D) reduced STAT5 activation, proliferation, and colony formation.
- KDELR1 depletion impaired the ability of FLT3-ITD-expressing cells to induce leukemia in a murine model.
Conclusions:
- Intracellular protein transport pathways are critical for FLT3-ITD oncogenic activity.
- KDELR1 acts as a positive modulator of FLT3-ITD signaling and is a potential therapeutic target in AML.
- Targeting protein transport mechanisms offers a promising strategy for treating FLT3-ITD-driven leukemias.
